Delta Research Partners | Monroe, LA

Research site

(Unclaimed)

Location

608 Grammont Street, Monroe, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Mirikizumab

Filgotinib

Metoclopramide

GB004

Remimazolam

Obeticholic Acid

AST-120

Relamorelin

Cilofexor

Diltiazem Hydrochloride

Parent organization

This site is a part of Delta Research Partners

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 49 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling

Crohn's Disease

Drug: Mirikizumab

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical resp...

Active, not recruiting

Ulcerative Colitis

Drug: Placebo SC

Drug: Mirikizumab SC

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-URGE)

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Active, not recruiting

Ulcerative Colitis Chronic

Ulcerative Colitis

Drug: Mirikizumab

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Enrolling

Ulcerative Colitis

Drug: Mirikizumab

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTIONLTE)

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy...

Active, not recruiting

Ulcerative Colitis

Drug: Filgotinib

Drug: Placebo

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis

Drug: Survodutide

Drug: Placebo matching survodutide

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

This study is open to adults who are at least 18 years old and have:* a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Liver Fibrosis

Drug: Survodutide

Drug: Placebo

Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC) (PL8177-205)

The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get...

Enrolling

Ulcerative Colitis Flare

Ulcerative

Drug: PL8177 Placebo

Drug: PL8177

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting

Nonalcoholic Steatohepatitis

Drug: Cilofexor (CILO)/Firsocostat (FIR)

Drug: PTM SEMA